The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Emerging precision approaches for metastatic pancreatic cancer
Wungki Park, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY, explores the urgent need for innovative treatments in metastatic pancreatic cancer, where survival rates are low, and many patients present with stage four disease at diagnosis. Current options are limited to chemotherapy up to the second line. Anticipated advancements in the next five years aim to transform clinical outcomes and treatment paradigms. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
